CareDx raised its full-year sales and earnings forecast after reporting second-quarter revenue that surged 52% year over year to $132 million. The precision medicine diagnostics company now expects full-year revenue of $490 million to $500 million, up from a prior forecast of $447 million to $465 million, and adjusted EBITDA of $66 million to $78 million, up from $43 million to $57 million. Adjusted net income more than tripled to $20 million, or $0.37 per share, well above Wall Street estimates of $0.23. The company said demand for its non-invasive transplant monitoring tests was strong, and it recently completed the acquisition of oncology diagnostics provider Naveris.
CareDx IncRaises full-year guidance and reports strong Q2 earnings, beating estimates.